在类固醇依赖性性结肠炎中广泛的未引起的血栓栓塞:一个病例报告
Hassaan Arshad1, Mohammad Abu-Abaa1, Sindhu Chadalawada1
1Internal Medicine, Capital Health Regional Medical Center, Trenton, USA.
Cureus
|May 30, 2023
概括
患有炎症性肠病 (IBD) 的患者面临更高的血栓塞栓症 (TE) 风险. 这一案例突出了IBD患者广泛的静脉血栓和肺栓塞,强调了临床怀疑的必要性.
科学领域:
- 血管医学 血管医学
- 胃肠病学 胃肠病学
- 内部医学 内部医学
背景情况:
- 炎症性肠病 (IBD) 与血栓栓塞 (TE) 的风险增加有关.
- 性结肠炎 (UC) 是一种常见的IBD形式,需要持续治疗.
- 类固醇依赖性疾病表明UC的挑战性过程.
研究的目的:
- 在患有性结肠炎的患者中报告一种罕见的广泛静脉血栓栓塞的病例.
- 为了强调IBD患者中TE的风险增加,即使在缓解期间.
主要方法:
- 一个70岁的病人患有类固醇依赖性性结肠炎的病例报告.
- 临床表现有运动性呼吸不全和腹痛.
- 诊断调查显示了广泛的静脉血栓和肺栓塞.
主要成果:
- 这位患者出现了广泛的双边阴,和马静脉血栓.
- 肺栓塞也被检测到.
- 这些发现强调了IBD患者中TE的罕见但严重的表现.
结论:
- 这一案例强调了在IBD患者中对TE的高度临床怀疑的迫切需要,特别是那些有不明原因的腹痛或损伤的患者.
- 早期诊断和治疗TE至关重要,以防止潜在的致命结果.
- 即使在缓解期内,IBD仍然是发生血栓栓塞事件的重要危险因素.
相关概念视频
Drugs for Treatment of Ulcerative Colitis in IBD
181
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
181
Inflammatory Bowel Disease I: Ulcerative Colitis
227
Introduction
Inflammatory bowel disease, or IBD, encompasses a group of disorders characterized by chronic inflammation or ulceration of the gastrointestinal tract.
Risk Factors
The exact cause of IBD remains unclear, although it is believed to be due to a mix of genetic, environmental, microbial, and immune factors. Genetic factors are significant in determining susceptibility to IBD, with family history being a critical risk factor. Individuals with a first-degree relative who has IBD are at...
Inflammatory bowel disease, or IBD, encompasses a group of disorders characterized by chronic inflammation or ulceration of the gastrointestinal tract.
Risk Factors
The exact cause of IBD remains unclear, although it is believed to be due to a mix of genetic, environmental, microbial, and immune factors. Genetic factors are significant in determining susceptibility to IBD, with family history being a critical risk factor. Individuals with a first-degree relative who has IBD are at...
227
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
161
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
161
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
205
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
205
Pulmonary Embolism I: Introduction
11
Pulmonary embolism (PE) occurs when a thrombus, fat or air embolus, amniotic fluid, or tumor tissue blocks one or more pulmonary arteries. These blockages originate in the venous system or the right side of the heart.EtiologyPE primarily arises from deep vein thrombosis (DVT) and other hypercoagulable states, such as inherited thrombophilias. Additional etiological factors include venous stasis, commonly seen in obesity, and endothelial injury from surgery and trauma. Less common causes include...
11
Drugs for Peptic Ulcer Disease: Prostaglandin Analogs as Mucosal Protective Agents
519
The gastric mucosa produces prostaglandins E2 (PGE2) and prostacyclin (PGI2), crucial in maintaining gastric health. They exert cytoprotective effects, including increasing bicarbonate secretion, releasing protective mucin, reducing gastric acid output, and preventing harmful vasoconstriction. These effects are mediated through various receptors, such as EP1, EP2, EP3, and EP4.
Non-steroidal anti-inflammatory drugs (NSAIDs) can induce peptic ulcers by inhibiting cyclooxygenase, decreasing...
Non-steroidal anti-inflammatory drugs (NSAIDs) can induce peptic ulcers by inhibiting cyclooxygenase, decreasing...
519


